Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature
Cynthia Fournier, Ian Hirsch, Anna Spreafico, Marcus O. Butler, Neesha C. Dhani, Maxwell Sauder
Abstract
Immune checkpoint inhibitors have revolutionized cancer treatment. They can induce cutaneous immune-related adverse events. One patient with immune-related eczema and two with immune-related bullous pemphigoid were successfully treated with dupilumab. Guidelines recommend the use of systemic steroids to manage moderate-to-severe cutaneous immune-related adverse events. They could potentially interfere with immunotherapy. There is a need to find alternative treatments that are safe in a cancer setting.
Topics & Concepts
MedicineAdverse effectImmune systemDupilumabImmunotherapyDermatologyAvelumabImmunologyCancerPembrolizumabInternal medicineAtopic dermatitisCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesChemotherapy-related skin toxicity